DE69635871T2 - Verfahren und Zusammensetzungen zur selektiven Modikation von Nukleinsäuren - Google Patents

Verfahren und Zusammensetzungen zur selektiven Modikation von Nukleinsäuren Download PDF

Info

Publication number
DE69635871T2
DE69635871T2 DE1996635871 DE69635871T DE69635871T2 DE 69635871 T2 DE69635871 T2 DE 69635871T2 DE 1996635871 DE1996635871 DE 1996635871 DE 69635871 T DE69635871 T DE 69635871T DE 69635871 T2 DE69635871 T2 DE 69635871T2
Authority
DE
Germany
Prior art keywords
use according
ethyleneimine
inactivation
blood
viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE1996635871
Other languages
German (de)
English (en)
Other versions
DE69635871D1 (de
Inventor
Edward I. Brookline Budowsky
Samuel K. Weston Ackerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panacos Pharmaceuticals Inc
Original Assignee
Panacos Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacos Pharmaceuticals Inc filed Critical Panacos Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69635871D1 publication Critical patent/DE69635871D1/de
Publication of DE69635871T2 publication Critical patent/DE69635871T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/12—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10161—Methods of inactivation or attenuation
    • C12N2730/10163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32461—Methods of inactivation or attenuation
    • C12N2770/32463—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18161—Methods of inactivation or attenuation
    • C12N2795/18163—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Peptides Or Proteins (AREA)
DE1996635871 1995-08-29 1996-08-29 Verfahren und Zusammensetzungen zur selektiven Modikation von Nukleinsäuren Expired - Fee Related DE69635871T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US521245 1995-08-29
US08/521,245 US6114108A (en) 1995-08-29 1995-08-29 Methods and compositions for the selective modification of viral nucleic acids

Publications (2)

Publication Number Publication Date
DE69635871D1 DE69635871D1 (de) 2006-05-04
DE69635871T2 true DE69635871T2 (de) 2007-05-24

Family

ID=24075988

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1996635871 Expired - Fee Related DE69635871T2 (de) 1995-08-29 1996-08-29 Verfahren und Zusammensetzungen zur selektiven Modikation von Nukleinsäuren
DE69621161T Expired - Fee Related DE69621161T2 (de) 1995-08-29 1996-08-29 Verfahren und zusammensetzungen zur selektiven modifikation von nukleinsaeuren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69621161T Expired - Fee Related DE69621161T2 (de) 1995-08-29 1996-08-29 Verfahren und zusammensetzungen zur selektiven modifikation von nukleinsaeuren

Country Status (18)

Country Link
US (1) US6114108A (https=)
EP (2) EP0915648B1 (https=)
JP (2) JP2001520635A (https=)
KR (1) KR100486765B1 (https=)
AT (2) ATE217144T1 (https=)
AU (1) AU694892B2 (https=)
BR (1) BR9610306A (https=)
CA (1) CA2230671A1 (https=)
DE (2) DE69635871T2 (https=)
DK (1) DK0915648T3 (https=)
ES (1) ES2173314T3 (https=)
HK (1) HK1042254A1 (https=)
IL (1) IL123467A0 (https=)
NO (1) NO980881L (https=)
NZ (1) NZ316787A (https=)
PL (1) PL187759B1 (https=)
PT (1) PT915648E (https=)
WO (1) WO1997007674A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691132A (en) 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US6177441B1 (en) 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
US20040048235A1 (en) * 1995-08-29 2004-03-11 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
DE19633684A1 (de) * 1996-08-12 1998-02-19 Dirk Dipl Ing Vollenbroich Verfahren zur Inaktivierung von lipidumhüllten Viren
US6514987B1 (en) 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6352695B1 (en) * 1997-10-03 2002-03-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US7569342B2 (en) 1997-12-10 2009-08-04 Sierra Molecular Corp. Removal of molecular assay interferences
JP4643004B2 (ja) 1998-01-06 2011-03-02 シーラス コーポレイション 生体材料中の病原体不活性化剤をクエンチするための方法
US6369048B1 (en) * 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
WO1999063981A2 (en) 1998-06-11 1999-12-16 Cerus Corporation Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells
DE19827750C1 (de) 1998-06-22 1999-07-29 Centeon Pharma Gmbh Verfahren zum Abtrennen von HIV aus einer Flüssigkeit
US6099734A (en) * 1998-07-08 2000-08-08 Baxter International Inc. Apparatus, membranes and methods for removing organic compounds from a biological fluid
US6908553B1 (en) 1998-07-08 2005-06-21 Baxter International Inc. Composite membrane with particulate matter substantially immobilized therein
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
DE19836559A1 (de) 1998-08-12 2000-03-23 Antigen Gmbh Gefäß zur Entnahme von Blut
JP2002525131A (ja) * 1998-09-25 2002-08-13 ブイ．アイ． テクノロジーズ インク． 生物学的組成物においてウイルスを選択的に不活化する方法
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
AU4678300A (en) 1999-04-30 2000-11-17 Slil Biomedical Corporation Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
AU2002243363A1 (en) * 2000-11-06 2002-07-24 V.I. Technologies, Inc. Use of aziridino-compounds in the treatment of immune dysfunctions
US6602718B1 (en) 2000-11-08 2003-08-05 Becton, Dickinson And Company Method and device for collecting and stabilizing a biological sample
US20020131958A1 (en) * 2001-01-22 2002-09-19 John Chapman Method for purifying a biological composition
US6635679B2 (en) * 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
WO2002092806A1 (en) * 2001-05-15 2002-11-21 V.I. Technologies, Inc. Apparatus for the inactivation of pathogens in protein-containingfluids
IL161428A0 (en) 2001-10-16 2004-09-27 Slil Biomedical Corp Oligoamine derivatives, methods for the production thereof and pharmaceutical compositions containing the same
JP2005517023A (ja) * 2001-11-06 2005-06-09 ヴイ．アイ．テクノロジーズ，インコーポレーテッド アジリジン化合物の治療的使用
EP1459724B1 (en) 2001-12-28 2013-11-20 Terumo Kabushiki Kaisha Blood bag system and method of inactivating pathogenic microorganisms
US20050074743A1 (en) * 2003-10-06 2005-04-07 Purmal Andrei A. Method and composition for treating a biological sample
PL1838355T3 (pl) 2004-10-29 2014-01-31 Cerus Corp Ulepszone sposoby wygaszania dla procesu inaktywacji czerwonych krwinek
EA023596B1 (ru) 2008-04-09 2016-06-30 Сирус Корпорейшн Способы обработки композиции эритроцитов для инактивации патогена
EP2855513B1 (en) * 2012-06-01 2016-12-07 Boehringer Ingelheim Vetmedica GmbH Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof
CN108603176B (zh) 2015-11-01 2022-10-21 格里科贝克有限责任公司 无病毒细胞系及获得其的方法
AU2017261705B2 (en) 2016-05-10 2024-04-18 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
KR102198877B1 (ko) 2019-07-16 2021-01-05 정소영 블루 라이트 차단 필터
CN113322252B (zh) * 2020-12-28 2026-04-03 广州凯普医药科技有限公司 一种拭子样本保存液

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492289A (en) * 1966-06-13 1970-01-27 Dow Chemical Co Polymers of alkylenimines
US4058599A (en) * 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
US4036952A (en) * 1973-02-24 1977-07-19 Bayer Aktiengesellschaft Ethyleneimine inactivated microorganisms
RU594771C (ru) * 1973-05-07 1993-07-07 Всесоюзный научно-исследовательский ящурный институт Средство дл инактивации вирусов при изготовлении противовирусных препаратов
US4841023A (en) * 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids
US5000951A (en) * 1987-03-09 1991-03-19 Diamond Scientific Company Multivalent canine distemper virus vaccine
US5055485A (en) * 1988-12-02 1991-10-08 New York Blood Center, Inc. Inactivation of viruses in cell- and protein-containing compositions using aryl diol epoxides
RU1768636C (ru) * 1989-08-16 1992-10-15 Всесоюзный научно-исследовательский ветеринарный институт птицеводства Способ получени антигена вируса болезни Гамборо
US5232844A (en) * 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5120649A (en) * 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
EP0500893A4 (en) * 1990-09-04 1993-03-10 Edward Shanbrom Preservation of blood, tissues and biological fluids
GB9108682D0 (en) * 1991-04-23 1991-06-12 Wellcome Found Production of vaccines
FR2679253B1 (fr) * 1991-07-15 1994-09-02 Pasteur Institut Proteines de resistance a la cycloheximide. utilisation comme marqueur de selection par exemple pour controler le transfert d'acides nucleiques.
EP0612532A3 (en) * 1993-02-26 1998-02-04 Solvay Animal Health, Inc. Canine coronavirus vaccine from feline enteric coronavirus
WO1996039818A1 (en) * 1995-06-07 1996-12-19 Cerus Corporation Treating red blood cell solutions with anti-viral agents

Also Published As

Publication number Publication date
KR19990044303A (ko) 1999-06-25
NZ316787A (en) 1999-11-29
BR9610306A (pt) 1999-07-06
JP2003176238A (ja) 2003-06-24
ATE319483T1 (de) 2006-03-15
DE69621161D1 (de) 2002-06-13
WO1997007674A1 (en) 1997-03-06
ES2173314T3 (es) 2002-10-16
IL123467A0 (en) 1998-09-24
HK1042254A1 (en) 2002-08-09
CA2230671A1 (en) 1997-03-06
NO980881L (no) 1998-04-27
AU694892B2 (en) 1998-07-30
EP0915648A1 (en) 1999-05-19
PL325338A1 (en) 1998-07-20
NO980881D0 (no) 1998-02-27
DE69621161T2 (de) 2002-11-21
DE69635871D1 (de) 2006-05-04
EP0915648B1 (en) 2002-05-08
US6114108A (en) 2000-09-05
AU6909996A (en) 1997-03-19
JP2001520635A (ja) 2001-10-30
PT915648E (pt) 2002-09-30
EP1129728A1 (en) 2001-09-05
EP1129728B1 (en) 2006-03-08
DK0915648T3 (da) 2002-08-26
PL187759B1 (pl) 2004-10-29
ATE217144T1 (de) 2002-05-15
KR100486765B1 (ko) 2005-09-02
EP0915648A4 (https=) 1999-05-19

Similar Documents

Publication Publication Date Title
DE69635871T2 (de) Verfahren und Zusammensetzungen zur selektiven Modikation von Nukleinsäuren
DE3855220T2 (de) Methode zur beseitigung von infektionserregern in geweben
AU750540B2 (en) Methods and compositions for the selective modification of nucleic acids
DE69227400T2 (de) Impfstoffe und Verfahren zu ihrer Herstellung
US6617157B1 (en) Methods and compositions for the selective modification of nucleic acids
DE69215355T2 (de) Stabilisierter Varizella-Lebendimpfstoff
DE3886332T2 (de) Inaktivierung von Viren und Bakterien.
DE69434445T2 (de) Verfahren zur sterilisation biologischer zusammensetzungen und das dabei erhaltene produkt
EP3024487B1 (de) Verfahren zur inaktivierung von viren unter verwendung von elektronenstrahlen
DE3805459A1 (de) Verfahren zur sterilisation von blut, plasma, blut- und plasmaderivaten, zellsuspensionen oder dgl.
EP0900087B1 (de) Verfahren zur desintegration von nucleinsäuren und herstellung von qualitätsgesicherten biologischen produkten
DE69227805T2 (de) Verwendung von Tri-n-Butylphosphat bei niedrigem pH in Lösungen von biologisch aktiven Proteinen für eine verbesserte viruzide Wirkung
Budowsky et al. Principles of selective inactivation of viral genome. V. Rational selection of conditions for inactivation of the viral suspension infectivity to a given extent by the action of β-propiolactone
EP1389133B1 (en) Methods for inactivating viruses
US20030202986A1 (en) Methods and compositions for the selective modification of nucleic
EP0234405A2 (de) Verwendung eines immunglobulinhaltigen Präparates zur Prophylaxe und Therapie von AIDS beim Menschen
DE2528584A1 (de) Verfahren zur inaktivierung der virusinfektiositaet unter gleichzeitiger stabilisierung von virusantigenen
DE3587351T3 (de) Hämoglobin mit reduziertem virusrisiko und dessen herstellung.
US20040048235A1 (en) Methods and compositions for the selective modification of nucleic acids
DE1076892B (de) Verfahren zur Herstellung eines Impfstoffes zur gleichzeitigen Immunisierung von Hunden oder Fuechsen gegen die Staupe und Hepatitis contagiosa canis
Kaplan Rabies vaccines--an assessment
DE102020108453A1 (de) Verfahren zur Bereitstellung eines Vakzins
RU95110953A (ru) Применение метода электрофоретического анализа для технологического контроля полноты инактивации убитых вакцин при использовании в качестве инактиватора сернокислой меди
DE10021433A1 (de) Verfahren zur Herstellung eines antiviralen Mittels

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: PANACOS PHARMACEUTICALS, INC., WATERTOWN, MA., US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee